Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

iThera Medical reports initiation of fifth clinical site in ongoing study for the non-invasive assessment of inflammatory bowel disease

Leave a comment

[ad_1]


MUNICH, Germany (PRWEB)

IBD is a chronic condition marked by recurring phases of inflammation and remission of the gastrointestinal tract. For many patients, adequate treatment can help to effectively manage the symptoms of the disease and help improve their quality of life. However, therapy failure occurs in 30-50 percent of patients, making it necessary to closely monitor inflammatory activity of the bowel throughout treatment management.

The current gold standard method to examine the bowel wall in IBD diagnosis and monitoring is endoscopy — an inherently invasive procedure that requires bowel preparation and sedation. Not only does endoscopy pose a significant burden for patients, but it also carries an additional risk of complications. A non-invasive alternative method of assessment could allow for more frequent monitoring, improve clinical understanding of disease status, and lead to better-informed decisions regarding choice of therapy.

Multispectral Optoacoustic Tomography (MSOT) is a new diagnostic imaging method based on the conversion of light energy into sound waves – also known as the photoacoustic effect. This technique combines pulsed laser excitation of tissue with ultrasound detection to allow non-invasive assessment of inflammation in the bowel wall. Through previous pilot studies, MSOT has already demonstrated its clinical value in IBD, where the technology may offer an effective alternative to endoscopy to monitor disease status.

The €2.3 million Horizon 2020 research project EUPHORIA (Enhancing Ultrasound and PHOtoacoustics for Recognition of Intestinal Abnormalities) led by iThera Medical aims to assess the ability of MSOT to measure disease activity in patients with IBD. Clinical validation of the diagnostic performance of the MSOT Acuity Echo investigational device is underway in a multicenter international study, with the I.R.C.C.S. San Raffaele Hospital (HSR) in Milan now added as the latest initiated site and the second site in Italy.

The initiation of new study sites will allow for faster patient recruitment to acquire data necessary for the clinical validation of the MSOT technology in the application of disease monitoring in IBD. Furthermore, iThera Medical will use the feedback from the various patient and investigator groups to guide the ongoing development of the MSOT technology to best benefit doctors and their patients.

Dr. Mariangela Allocca – a leading physician at HSR’s department of Gastroenterology and Gastrointestinal Endoscopy as well as EUPHORIA’s principal investigator at the Milan study site – comments on the site’s participation in EUPHORIA: “We are very excited about the initiation of HSR, and we hope to strongly contribute to the ongoing clinical validation for the use of MSOT technology in the non-invasive assessment of IBD.”

EUPHORIA marks a key step towards establishing MSOT as a competitor in the broader medical imaging market and offering a better way to monitor IBD.

For more information on the EUPHORIA project, visit: http://www.euphoria2020.eu

About iThera Medical

Since its incorporation in 2010, iThera Medical develops and markets optoacoustic imaging systems for preclinical and clinical research. More recently, the company has started translating its technology for routine diagnostic clinical use across various types of diseases, including cancer, inflammatory, fibrotic, and cardiovascular diseases. Optoacoustic imaging utilizes the photoacoustic effect – the conversion of light energy into acoustic signals – to visualize and quantify optical contrast in deep tissue, at high spatial and temporal resolution. For details, see: http://www.ithera-medical.com

The EUPHORIA Project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 830965. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.

For further information, please contact:

Christian Wiest

Phone: +49 (0)89 700 7449-21

Email: christian.wiest@ithera-medical.com

Share article on social media or email:

[ad_2]

Health

American Gene Technologies Appoints Dr. Jeff Boyle as Chief Science Officer

Leave a comment

[ad_1]

News Image

Science is at the heart of everything we do at American Gene Technologies, and Dr. Boyle’s background as a science-based C-suite executive is exactly what we need to expand our R&D team and drug pipeline. -American Gene Technologies CEO Jeff Galvin


ROCKVILLE, Md. (PRWEB)

American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue the developments in monogenic disease and immuno-oncology.

Most recently, Dr. Boyle was president of Ellume USA LLC. He built Ellume’s U.S. organization from the ground up, constructing and commissioning an automated manufacturing facility for COVID-19 home tests in partnership with the Department of Defense. He also served as board members on the Maryland Technology Council and BioHealth Innovation.

“Science is at the heart of everything we do at American Gene Technologies, and Dr. Boyle’s background as a science-based C-suite executive is exactly what we need to expand our R&D team and drug pipeline,” said CEO Jeff Galvin. “His drug development experience and his recent role scaling up Ellume’s COVID diagnostic technology product line is directly relevant to American Gene Technologies’ current trajectory. Dr. Boyle’s science and business expertise will be strategic to continue to build our drug development platform as well as specific disease applications on that technology.”

Prior to Ellume, Boyle held multiple executive roles at QIAGEN, a ​​leading global provider of sample-to-insight solutions to more than 500,000 customers in molecular diagnostics (human healthcare), applied testing (primarily forensics), pharma (pharma and biotech companies) and academia (life sciences research).

“I look forward to building on the successes of Jeff Galvin and the team at American Gene Technologies as we grow the expertise with the pipeline in our mission to relieve human suffering from serious diseases with our gene therapy platform,” Jeff Boyle said.

Boyle is an inventor listed on several patents in fields including vaccines, immuno-oncology and medical devices that have been launched as revenue-generating products globally. He has broad experience in responding to examiners, opposition proceedings, and has participated in the defense and prosecution of a variety of IP assets. He has managed IP portfolios, and executed on strategic initiatives to develop and in-license IP necessary for product development and market protection.

The scope of his patent work includes diagnostics utilizing the optimal stimulation of CD4 and CD8 T cells and ability to differentiate using simple analytical techniques; diagnostics utilizing the stimulation of both innate and adaptive immune responses to assess immune function; peptide epitopes for T cell based diagnostics; antigen targeting to sites of immune induction including DNA vaccines; and combination of biologics and immune stimulatory complexes for oncology therapies.

About HIV

According to UNAIDS, approximately 37.7 million people worldwide live with HIV/AIDS. In the United States, government statistics show 1.2 million people have HIV and estimate that 34,800 Americans were newly infected with HIV in 2019. Across the globe, UNAIDS estimates that approximately 1.5 million individuals were newly infected with HIV in 2020. The Washington D.C./Baltimore area is often cited as a ‘hot spot’ for HIV, with Washington, D.C., having the highest rate of infection at nearly 46 cases per 100,000 population and Baltimore City having rates of 17 cases per 100,000. Maryland also ranks sixth among U.S. states and territories in HIV diagnosis rates, with more than 900 new cases in 2019 alone, according to the Maryland Department of Health.

Since the late 1980s, antiretroviral drugs have restored quality of life to persons living with HIV and, in some cases, have even been used to prevent new infections. However, no approved treatment has demonstrated the ability to cure HIV. American Gene Technologies is committed to addressing this unmet medical need.

About AGT103-T

AGT103-T is a genetically modified cell product made from a person’s own cells. American Gene Technologies’ unique approach focuses on permanently repairing the key immune system damage caused by HIV. American Gene Technologies’ goal is to develop a gene therapy capable of repairing the immune system so it will provide natural control over HIV replication.

About American Gene Technologies

American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. American Gene Technologies has been granted four patents for the technology used to make AGT103-T and 11 patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. American Gene Technologies’ treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

Video About American Gene Technologies’ Work: https://youtu.be/fiA2s7JCkJ8

Share article on social media or email:

[ad_2]

Health

New York City’s Booming Life Sciences Sector Driven By Investment and Real Estate Development

Leave a comment

[ad_1]

Tower Two at Hutchinson Metro Center

The presence of almost 5,100 life-sciences companies in this area is a tremendous opportunity for real estate developers,” said Joe Simone, President of Simone Development Companies.


BRONX, N.Y. (PRWEB)

New construction of life-sciences real estate in New York City is driven by ample talent pools, venture capital and government support, said Joseph Simone of Simone Development Companies.

“The New York City region is now the nation’s largest life-sciences economy with more than a dozen innovation clusters. The presence of almost 5,100 life-sciences companies in this area is a tremendous opportunity for real estate developers,” said Joe Simone, President of Simone Development.

According to a new report, the life sciences economy in the New York City metropolitan area generated more than $23 billion in wages in 2021. The report by the New York City Economic Development Corporation (NYCEDC) noted that over the last decade, more than 800 new diagnostic testing labs have opened in the region, a growth of 26%.

One of the thriving innovation clusters cited by the NYCEDC report is in the Bronx’s Morris Park neighborhood, where the Montefiore-Einstein Accelerated Biotechnology Research Center will soon open. This biomanufacturing operation will focus on cell, gene, and antibody therapy production.

Simone Development Companies’ 42-acre Hutchinson Metro Center is across the street from the Albert Einstein College and Montefiore Medical Center. The campus is anchored by Montefiore, which occupies the entirety of Tower Two and parts of Tower One.

“The launch of the Montefiore-Einstein biomanufacturing operation coincides with our planned expansion of the Hutchinson Metro Center campus to include life-science-focused laboratories for medical research,” said Patricia Simone, President of Simone Management Group. “As the NYCEDC report noted, the life-sciences sector depends on proximity and interactions among researchers, funders and entrepreneurs as they develop new technologies.”

The tristate New York area has more than 5.6 million square feet of new lab space under development. In recent years, New York City clarified its land-use rules to allow more lab and research spaces.

Simone Development Companies is a fully integrated private real estate investment and development company that acquires and develops healthcare, mixed-use, office, industrial, retail and residential properties. Headquartered at the Hutchinson Metro Center, it boasts a portfolio of over 7 million square feet throughout the Bronx, Manhattan, Queens, Long Island, Westchester, Orange and Fairfield Counties and New Jersey. With services spanning acquisition, development, construction, finance, asset management, accounting, leasing and property management, Simone Development Companies is set apart by its creatively oriented management team, long-term asset ownership and its pursuit of visionary development.

Share article on social media or email:

[ad_2]

Health

Oshi Health Names Dr. John Allen to Medical Advisory Board

Leave a comment

[ad_1]

Oshi Health is redesigned digestive care

“The future of GI care requires collaboration between traditional practices and digital-first providers like Oshi Health that can deliver whole-person care protocols and deep, data-driven insights,” said Dr. Allen.


NEW YORK (PRWEB)

Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that John Allen, MD, MBA, AGAF has joined its medical advisory board.

An internationally renowned gastroenterologist and leader in the field who built one of the largest private practices in the United States, Dr. Allen has recently retired as the Chief Clinical Officer at the University of Michigan Medical Group and has been a past President & Chairman of the American Gastroenterological Association (AGA). He will apply his deep experience and expertise to help Oshi Health continue to expand its innovative, virtual-first care delivery protocols.

“Traditional GI practices are under intense pressure with more people seeking medical help, changes in payment and technology models, and fewer available physicians,” said Dr. Allen. “The future of GI care requires collaboration between traditional practices and digital-first providers like Oshi Health that can deliver whole-person care protocols and deep, data-driven insights. Together, I believe they can better serve the needs of today’s patients in a way that aligns with the principles of value-based care for our specialty.”

Prior to serving as the Chief Clinical Officer at the University of Michigan Medical Group and as a Clinical Professor of Medicine at the University of Michigan Medical School, Dr. Allen was the Clinical Chief of the GI Division at Yale University School of Medicine and Quality Committee Chair and member of the Governing Board at Allina Hospitals & Clinics in the Twin Cities of Minnesota. Prior to his tenure at Yale, he was the Chief Medical Officer at Minnesota Gastroenterology, P.A.

In addition to his past roles as the President & Chairman of the AGA, he continues to serve as the organization’s secretary and treasurer. Dr. Allen was also an editor for Practice Management for Clinical Gastroenterology and Hepatology, a leading scientific journal for gastroenterologists.

“We are honored to welcome Dr. Allen to the Oshi Health family,” said Oshi Health CEO Sam Holliday. “He is a highly respected and distinguished leader in the field who has contributed to this specialty from nearly every conceivable perspective. His insights and guidance have already proven invaluable as we continue to scale and build relationships with clinical leaders across the country.”

Oshi Health’s integrated GI care model provides effective relief through evidence-based, whole-person care — including often-neglected dietary and psychosocial interventions — and can quickly achieve a diagnosis and guide individualized treatment.

Patients connect with specialized providers via telehealth visits, their care plan is continuously informed and refined by their symptoms, food and bowel movement monitoring, and a health coach provides daily messaging and support to make sustainable lifestyle changes.

Oshi Health members often achieve symptom control within 90 days and 91% of members report that Oshi Health helped them improve their quality of life.

About Oshi Health Inc.

Oshi Health is a completely redesigned gastrointestinal care experience. Its virtual, patient-centered care delivery model is built to provide diagnosis and multidisciplinary care for GI conditions, and to empower people to gain significant and lasting control of their symptoms and improve their quality of life. Oshi Health works with innovative employers and health insurance partners to scale access to their employees and members as a covered benefit, in turn, reducing overall healthcare cost and improving productivity in life and at work. Oshi Heath was launched in 2020 to improve the lives of people with gastrointestinal diseases. For more information, visit http://www.oshihealth.com.

###

Media Contact

Stephanie Hicks

Cosmo Public Relations, Inc for Oshi Health

805/295-9455

stephanie@cosmo-pr.com

Share article on social media or email:

[ad_2]

Health

Mount Sinai Researcher Receives Prestigious Award From the American Association of Indian Scientists in Cancer Research

Leave a comment

[ad_1]

“It was a wonderful surprise to receive this award and to join such a prestigious group of previous recipients,” said Dr. Bhardwaj.


NEW YORK (PRWEB)

Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).

The AAISCR’s Lifetime Achievement award is presented annually to an outstanding scientist who has made significant contributions to cancer research, either through a scientific discovery or through their body of work. These contributions, whether through research, leadership, or mentorship, must have a lasting impact and demonstrate a lifetime commitment to achieving progress against cancer.

Through her research, Dr. Bhardwaj has significantly advanced the understanding of how to fight cancer by using innate immune cells to reverse immunosuppression in tumor microenvironments. In particular, her team discovered a subset of dendritic cells, which play a key role in initiating an immune response. Subsequently she gained further insights on how dendritic cells work by generating and growing them in her lab. Dr. Bhardwaj also developed dendritic-cell-based and dendritic-cell-targeted vaccines for the treatment of both cancer and infection in several investigator-initiated studies and has pioneered neoantigen vaccine studies at The Tisch Cancer Institute.

Prior to receiving this award, Dr. Bhardwaj was named one of Scientific American’s Top 50 researchers, receiving the Award for Medical Research in 2004, and in 2015 she received the Fred W. Alt Award for new discoveries in Immunology from the Cancer Research Institute. Dr. Bhardwaj has served on numerous National Institutes of Health Study Sections and advisory councils and as chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research, where she also serves on the Board of Directors. She has secured multiple federal and foundation grants and has authored more than 200 publications over the course of her career.

“It was a wonderful surprise to receive this award and to join such a prestigious group of previous recipients,” said Dr. Bhardwaj, Medical Director of the Vaccine and Cell Therapy Laboratory, Co-Director of the Cancer Immunology Program, Ward-Coleman Chair in Cancer Research, and Professor of Medicine (Hematology and Medical Oncology), and Urology, at the Icahn School of Medicine at Mount Sinai. “It was also extraordinary to be recognized by such an elite group of peers. When I started in this field, dendritic cells were not considered unique lineages and were thought to be a lesser sibling of monocytes. But with the support of Mount Sinai and, in particular, The Tisch Cancer Institute, we were able to make significant discoveries that helped to expand this field and led to many studies using dendritic cells as cellular vaccine adjuvants. Ultimately, it is exciting to have our efforts validated with this award and it inspires me to continue my work and advance the fight against cancer.”

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, over 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in three pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, on Twitter and YouTube.

Share article on social media or email:

[ad_2]

Health

uMotif and ClinOne Unify eCOA/ePRO and eConsent to Improve the Participant Experience and Endpoint Data Quality in Global Clinical Trials

Leave a comment

[ad_1]

News Image

ClinOne is proud to provide our eConsent customers direct access to uMotif’s intuitive, trusted eCOA/ePRO. Our expanded platform provides essential solutions that blend clinical trial activities into the flow of everyday life, making it easier to participate in a study. – Andrea Valente, ClinOne CEO


LONDON and BOSTON (PRWEB)

uMotif and ClinOne today announced a partnership to provide the global life sciences industry with a single, integrated solution underpinned by an intuitive user experience that results in best-in-class electronic clinical outcome assessments (eCOA) and electronic informed consent (eConsent) technology.

Today many patients and clinical research coordinators struggle to navigate a changing constellation of systems, apps, and sensors for each individual protocol. Both patient and site participants consistently rank multiple and duplicative logins, trainings, and data entry along with inconsistent user experiences as top challenges to sustain clinical trial participation.

uMotif and ClinOne built their platforms with extensibility and intuitive user experiences at their core. Together they feature the inherent flexibility to support fully decentralized trials (DCT), traditional site-based studies, and hybrid designs of any scale or therapeutic area complexity. The combined offering is cost-accessible, fast to deploy, and easy for participants to use on their own familiar mobile devices.

“It is encouraging and refreshing to see so many sponsors and CROs adopt patient-first technologies like eCOA, ePRO (patient reported outcomes) and eConsent, but too often they are frustrated by disjointed solutions that place a high burden on users and limit effectiveness,” said Steve Rosenberg (LinkedIn), CEO of uMotif. “Together, uMotif and ClinOne are setting out to directly address these pain points with a seamless and comprehensive solution that trial participants actually want to use. In this way, we will add immediate value to increase data quality and reduce risk while improving convenience and comfort for everyone involved with the trial.”

uMotif’s eCOA/ePRO and engagement platform improves participant experience, transforming the reliability of patient-reported and site-based endpoint data used for new drug approval decisions. eConsent on ClinOne’s adaptive experience platform reduces the risk of consent-related errors and enables more informed participation decisions. Together they provide a seamless participant experience across a wide array of therapeutic areas and trial designs.

“The work our customers do to save and improve lives is nothing short of inspiring, and as a technology ecosystem we share a responsibility to provide the patients, caregivers, and sites in their trials with the best experience possible,” said Andrea Valente (LinkedIn), ClinOne CEO. “Yet with the pandemic especially, too many untested products entered the market before they were ready from a user perspective. That’s why we are proud to provide our eConsent customers with direct access to an intuitive and trusted eCOA/ePRO solution from uMotif. With this partnership, our expanded platform continues to provide essential solutions that blend trial activities into the flow of everyday lives and make it easier for everyone to participate in a study.”

We invite you to join uMotif and ClinOne for the webcast “Elevate Participant Experience by Unifying eConsent, ePRO, and eCOA” on Thursday, July 21st at 11:00 AM ET / 4:00 PM GMT.

Register for the webcast here: https://register.gotowebinar.com/register/1732747186359631884

Or visit http://www.umotif.com and http://www.clinone.com.

About uMotif

uMotif’s mission is to put patients at the center of clinical research. Designed with patients for patients, the uMotif patient-first eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotech’s, CROs, and academic institutions to capture large volumes of eCOA/ePRO, symptom, and wearable device data. http://www.umotif.com

About ClinOne

ClinOne provides adaptive experiences for participants in clinical trials. By offering choice to patients, caregivers, and site staff, our technology makes it easier to stay active, compliant, and comfortable in a trial – thereby expanding enrollment access, reducing drop-out rate, and shortening conduct timelines. Our true single platform features solutions for local HCP trial awareness, remote and onsite eConsent, Uber Health, medication adherence, and a DCT portal. ClinOne stands alone with the industry’s fastest implementation (average 2-4 weeks), cost-efficient scale, and seamless API integrations for complex therapeutic areas such as Oncology, CNS, and Rare Disease in over 60 languages. To learn why more than 55 sponsors and CROs trust ClinOne in 100+ currently active studies to connect, inform, and empower participants to take control of their clinical trial experience, begin a conversation with our experts at http://www.clinone.com.

Share article on social media or email:

[ad_2]

Health

Visikol Announces the Launch of Novel Blood Brain Barrier Assay

Leave a comment

[ad_1]


HAMPTON, N.J. (PRWEB)

The BBB behaves as a highly selective semipermeable membrane separating circulating blood from the central nervous system while allowing the passage of glucose, water, and amino acids into the cerebrospinal fluid. It also protects brain nervous tissue from the fluctuation of plasma composition, from pathogenic agents, and maintains homeostasis of the brain parenchyma by restricting non-specific flux of ions, peptides, proteins and cells into and out the brain. The BBB is permeable to hydrophobic molecules and utilizes active transport to move ions, glucose and other critical molecules across the membrane. When functioning properly, the BBB is a complex barrier that must be overcome when trying to deliver therapeutics to the brain. Due to the challenges with therapeutics crossing the blood brain barrier, researchers need access to tools that can replicate this process in vitro.

According to Visikol CSO, Dr. Tom Villani, “The poor penetration of compounds across this barrier is responsible for the attrition of 95% of therapeutics that target regions of the brain.” By allowing for compound penetration across the BBB to be investigated in vitro, experimental data can be generated earlier in the development process at a higher throughput and lower cost when compared with animal studies. This model can be used for drug BBB permeability assays, research on BBB physiology, cell-cell interactions, and many other analyses. When combined with the Visikol portfolio of imaging and image analysis tools as well as chemical analysis approaches, Visikol is able to provide a truly differentiated assay for assessing the BBB.

The Visikol BBB assay leverages the Fujifilm iCell platform and incorporates the iCell Brain Microvascular Endothelial Cells, iCell Pericytes along with iCell Astrocytes in a transwell based model system. The model has demonstrated a high degree of BBB functionality and a high degree of correlation to expected in vivo results with compounds with known in vivo outcomes. If you are interested in working with Visikol and utilizing this BBB assay, please reach out to our team today to discuss further. Visikol offers end-to-end solutions leveraging this assay from compound to report.

For more information, please visit http://www.visikol.com/services/in-vitro/blood-brain-barrier/

Share article on social media or email:

[ad_2]

Health

Bizmatics and Zocdoc Partner to Drive Efficiency for Providers, Access for Patients

Leave a comment

[ad_1]

“PrognoCIS’s partnership with Zocdoc offers medical professionals greater access to new patients as well as better communication with existing patients while driving down costs,” says Vinay Deshpande, CEO and Co-founder of Bizmatics.


SAN JOSE, Calif. (PRWEB)

Bizmatics, a leading provider of clinical and business productivity software and services to ambulatory medical clinics, and Zocdoc, the leading healthcare marketplace that makes it easy for people to find and book in-person or virtual care across +200 specialties and +12k insurance plans, have announced a partnership to integrate Bizmatic’s Electronic Health Record (EHR) Software – PrognoCIS – with Zocdoc’s leading platform technology for new patient acquisition.

This interface enables patients to find doctors and book appointments online instantly. Any clinic using Zocdoc with PrognoCIS will have appointments booked via Zocdoc automatically transferred into PrognoCIS. Both new and existing patients can schedule appointments using Zocdoc, free of charge.

“PrognoCIS’s partnership with Zocdoc offers medical professionals greater access to new patients as well as better communication with existing patients while driving down costs,” says Vinay Deshpande, CEO and Co-founder of Bizmatics. “Patients will have greater transparency with their health care needs and better access to their medical practitioners.”

“We’re proud to partner with Bizmatics to help simplify Americans’ search for quality health care,” said Kate Kline, Zocdoc’s President of Health Systems. “Our continued growth with partners like Bizmatics is indicative of Zocdoc’s ongoing momentum in the healthcare space, and a milestone in our efforts to increase practice efficiency for providers while helping every type of patient to find and book every type of care.”

If you are a healthcare provider who wants to reach new patients or ease the scheduling process for existing patients, you can learn more at https://www.zocdoc.com/partner/prognocis.

About Zocdoc

Zocdoc is a leading digital healthcare marketplace for in-person or virtual care. Each month, millions of people use our free service, via Zocdoc.com or the Zocdoc app, to find in-network doctors, instantly book in-person or virtual appointments, read reviews from verified users, get reminders for upcoming appointments and preventive checkups, and more. With a mission to give power to the patient, Zocdoc’s platform delivers the accessible and simple experience they expect and deserve.

About Bizmatics: Now A Business Unit of Harris Computer

A leading EHR company, Bizmatics provides clinical and business productivity software and services to ambulatory medical clinics -small, large, and multi-specialty. Our cloud-based application, PrognoCIS is a fully integrated solution comprising of EHR, Telemedicine, Practice Management, Medical Billing and Patient Engagement tools.

Share article on social media or email:

[ad_2]

Health

YorLabs Names Timothy Marcotte as Chief Financial Officer

Leave a comment

[ad_1]

YorLabs is focused on alleviating these issues and providing an upgradable solution that will grow with organizations’ evolving imaging needs.


PORTLAND, Ore. (PRWEB)

YorLabs, a developer of cutting-edge intracardiac image guided therapy solutions, recently named Timothy “Tim” Marcotte as chief financial officer (CFO). Marcotte has more than 30 years of experience helping grow a wide variety of organizations with strong finance, controlling, equity and debt financing leadership. He also has been involved in leading patent licensing and initial public offerings (IPOs), as well as merger and acquisition transactions.

“It is a pleasure to work with Tim once again in his capacity as CFO,” said Glen McLaughlin, PhD, president and chief executive officer, YorLabs. “His breadth of experience will be highly beneficial in guiding YorLabs to a very successful outcome as we bring next generation solutions to intracardiac image guided therapy. His knowledge of the healthcare industry is extensive and will provide a tremendous asset for our efforts.”

Marcotte most recently was chief of finance and administration for the Edgewood Center for Children and Families, the oldest children’s nonprofit in the western United States. Prior to Edgewood, he served in similar capacities for small medical technology start-ups and mid-size organizations including Zonare Medical Systems, Inc., VNUS Medical Technologies and Sunrise Medical Technologies International. Marcotte holds a Masters of Business Administration and Bachelor of Science from the University of Michigan, Ann Arbor.

“I believe YorLabs will provide a solution that will reduce capital outlays and enable ongoing, state-of-the art visualization for interventional cardiology and electrophysiology labs,” said Marcotte. “These labs face several challenges including capital constraints and disparate systems. YorLabs is focused on alleviating these issues and providing an upgradable solution that will grow with organizations’ evolving imaging needs.”

The YorLabs solution is designed to provide automatic upgrades to maintain cutting-edge technology throughout the lifecycle of the platform. The company is developing world class, intracardiac image guided therapy performance with dedicated application and procedure based offerings. This solution will consist of an intuitive user interface platform, resulting in significant reduction of clutter, along with greatly enhanced workflow.

“It is exciting to add another industry veteran to our growing list of highly experienced executives,” said Anshumali Roy, founder and chief technical officer, YorLabs. “As we continue the development of our comprehensive intracardiac imaging solution, Tim’s background in addressing the financial needs of such endeavors will help ensure achieving our goals. We are excited to have him as part of the YorLabs team.”

About YorLabs

Today’s Cath Lab faces numerous challenges including capital constraints and disparate systems. YorLabs is developing a world class, intracardiac image guided therapy platform with dedicated application and procedural based settings. The YorLabs solution is designed to be an intuitive platform while eliminating large capital outlays and significantly enhancing workflow.

Share article on social media or email:

[ad_2]

Health

University of Medicine and Health Sciences to Host “LGBTQ+ Medicine & Theory: Providing Compassionate Care”

Leave a comment

[ad_1]

UMHS alumnus Soren Estvold, MD, MPS will present LGBTQ+ Medicine & Theory on June 22 at 7 pm EST

“We are excited to welcome Dr. Estvold back for a presentation focused on the unique healthcare needs of the LGBTQ+ population at a time when this community is facing renewed attacks and barriers to receiving medical care.”


NEW YORK (PRWEB)

The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, today announced that it will host a live stream event, “LGBTQ+ Medicine & Theory: Providing Compassionate Care,” on Wednesday, June 22 at 7 pm EDT. The discussion will be led by UMHS alumnus Soren Estvold, MD, MPH, a family medicine physician who specializes in treating LGBTQ+ patients at Augusta University Medical Center in Georgia and a volunteer physician at the Equality Clinic in Augusta, Georgia, a primary care clinic serving mostly transgender patients needing Hormone Replacement Therapy. The event will address key considerations for working with LGBTQ+ patients, describe how to provide compassionate care, offer practical advice for medical professionals and allies, and share resources for patients and providers. Following the presentation, current UMHS student Nisha Shetty will moderate a live Q & A session from the campus on St. Kitts. The event will be live-streamed on the UMHS YouTube channel as well as on the UMHS Facebook and LinkedIn pages. The presentation will also be recorded for future viewing.

“We are excited to welcome Dr. Estvold back for a presentation focused on the unique healthcare needs of the LGBTQ+ population at a time when this community is facing renewed attacks and barriers to receiving medical care,” said Warren Ross, president of UMHS. “We’re proud of Dr. Estvold’s accomplishments in LGBTQ+ medicine, and are honored that he has once again agreed to share his insights with our students and offer specific guidance to deliver better health outcomes for LGBTQ+ patients.”

During the “LGBTQ+ Medicine & Theory” event, Dr. Estvold will define “full-spectrum medicine” and highlight the unique healthcare considerations of each subgroup within the community. He will also address the gender minority stress framework and how that impacts LGBTQ+ patients. Additionally, Dr. Estvold will offer insights on how to create an LGBTQ+-friendly practice and share advice for students interested in pursuing a specialty in LGBTQ+ medicine.

The discussion is the latest in a series of live stream events featuring UMHS faculty and alumni sharing their expertise on topics targeted toward current and prospective medical students and healthcare professionals. Past events include:

  • “Pathways to Practicing Medicine in Canada: UMHS Alumni Share Their Experiences”

  • “UMHS Women in Medicine: A Conversation About the First Year of Residency,”

  • “Cardiology: A Discussion About Cardiac Care & Careers in Cardiology,”

  • “Non-Traditional Medical Students – Medical School Admissions and Residency Advisors Reveal All!”,

  • “Black Women in Medicine: A Conversation About the Black Experience”,

  • “Ask a Microbiologist,”

  • “Suicide Prevention and the State of Psychiatry.” and

  • “LGBTQ+ Medicine and Theory.”

Links to view all past discussions may be found by visiting this link.

To join “LGBTQ+ Medicine & Theory: Providing Compassionate Care,” on Wednesday, June 22, at 7 pm EDT visit the UMHS live events and meetings page.

About UMHS

The University of Medicine and Health Sciences (UMHS), is a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada. UMHS was founded in 2007 by medical education pioneers Warren and Robert Ross to deliver a highly personalized school experience. Graduates of UMHS earn a Doctor of Medicine degree (MD) and qualify to practice medicine throughout the United States and Canada. Students begin their Basic Science studies in St. Kitts, West Indies, and complete their clinical training in the United States. With an unprecedented 96% student retention rate, the vast majority of students that begin their medical studies at UMHS go on to obtain residencies. For more information, visit https://www.umhs-sk.org/.

Share article on social media or email:

[ad_2]